This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (97)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

The REALITY Trial: A Randomized Controlled Trial

Marie-Claude Morice, MD; Antonio Colombo, MD; Bernhard Meier, MD; Patrick Serruys, MD, PhD; Corrado Tamburino, MD; Giulio Guagliumi, MD; Eduardo Sousa, MD, PhD; Hans-Peter Stoll, MD; for the REALITY Trial Investigators

JAMA. 2006;295:895-904.

Context  Compared with bare metal stents, sirolimus-eluting and paclitaxel-eluting stents have been shown to markedly improve angiographic and clinical outcomes after percutaneous coronary revascularization, but their performance in the treatment of de novo coronary lesions has not been compared in a prospective multicenter study.

Objective  To compare the safety and efficacy of sirolimus-eluting vs paclitaxel-eluting coronary stents.

Design  Prospective, randomized comparative trial (the REALITY trial) conducted between August 2003 and February 2004, with angiographic follow-up at 8 months and clinical follow-up at 12 months.

Setting  Ninety hospitals in Europe, Latin America, and Asia.

Patients  A total of 1386 patients (mean age, 62.6 years; 73.1% men; 28.0% with diabetes) with angina pectoris and 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries.

Intervention  Patients were randomly assigned in a 1:1 ratio to receive a sirolimus-eluting stent (n = 701) or a paclitaxel-eluting stent (n = 685).

Main Outcome Measures  The primary end point was in-lesion binary restenosis (presence of a more than 50% luminal-diameter stenosis) at 8 months. Secondary end points included 1-year rates of target lesion and vessel revascularization and a composite end point of cardiac death, Q-wave or non–Q-wave myocardial infarction, coronary artery bypass graft surgery, or repeat target lesion revascularization.

Results  In-lesion binary restenosis at 8 months occurred in 86 patients (9.6%) with a sirolimus-eluting stent vs 95 (11.1%) with a paclitaxel-eluting stent (relative risk [RR], 0.84; 95% confidence interval [CI], 0.61-1.17; P = .31). For sirolimus- vs paclitaxel-eluting stents, respectively, the mean (SD) in-stent late loss was 0.09 (0.43) mm vs 0.31 (0.44) mm (difference, –0.22 mm; 95% CI, –0.26 to –0.18 mm; P<.001), mean (SD) in-stent diameter stenosis was 23.1% (16.6%) vs 26.7% (15.8%) (difference, –3.60%; 95% CI, –5.12% to –2.08%; P<.001), and the number of major adverse cardiac events at 1 year was 73 (10.7%) vs 76 (11.4%) (RR, 0.94; 95% CI, 0.69-1.27; P = .73).

Conclusion  In this trial comparing sirolimus- and paclitaxel-eluting coronary stents, there were no differences in the rates of binary restenosis or major adverse cardiac events.

Clinical Trial Registration  ClinicalTrials.gov Identifier: NCT00235092

Author Affiliations: Institut Cardiovasculaire Paris Sud, Massy, France (Dr Morice); Centro Cuore Colombus and San Raffaele Hospital, Milan, Italy (Dr Colombo); University Hospital, Bern, Switzerland (Dr Meier); Erasmus Medical Center, Rotterdam, the Netherlands (Dr Serruys); Ferrarotto Hospital, Catania, Italy (Dr Tamburino); Azienda Ospedaliera Ospedali Riuniti di Bergamo, Italy (Dr Guagliumi); Instituto Dante Pazzanese, Sao Paulo, Brazil (Dr Sousa); and Cordis Clinical Research Europe, Waterloo, Belgium (Dr Stoll).

RELATED ARTICLE

Wish List and REALITY: Choice of Stents and End Points for Treatment of De Novo Coronary Artery Lesions
Sorin J. Brener
JAMA. 2006;295(8):937-938.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
Mahmud et al.
J Am Coll Cardiol 2008;51:2385-2395.
ABSTRACT | FULL TEXT  

Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry.
Meliga et al.
J Am Coll Cardiol 2008;51:2212-2219.
ABSTRACT | FULL TEXT  

Are Surrogate End Points in Drug-Eluting Stent Trials Reliable?
Agostoni and Biondi-Zoccai
J Am Coll Cardiol 2008;51:1991-1992.
FULL TEXT  

Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Stone et al.
JAMA 2008;299:1903-1913.
ABSTRACT | FULL TEXT  

Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Billinger et al.
Eur Heart J 2008;29:718-725.
ABSTRACT | FULL TEXT  

Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
Kirtane et al.
J Am Coll Cardiol 2008;51:708-715.
ABSTRACT | FULL TEXT  

Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
Boutron et al.
ANN INTERN MED 2008;148:295-309.
ABSTRACT | FULL TEXT  

Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
Galloe et al.
JAMA 2008;299:409-416.
ABSTRACT | FULL TEXT  

Effectiveness of Drug-Eluting Stents in Real-World Patients
Mukherjee and Moliterno
JAMA 2008;299:454-455.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT  

Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
Pocock et al.
J Am Coll Cardiol 2008;51:23-32.
ABSTRACT | FULL TEXT  

A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
Schomig et al.
J Am Coll Cardiol 2007;50:1373-1380.
ABSTRACT | FULL TEXT  

The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
Kereiakes
J Am Coll Cardiol 2007;50:1381-1385.
FULL TEXT  

Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents: Results From a Large Prospective Multicenter Registry STENT Group
Simonton et al.
J Am Coll Cardiol 2007;50:1214-1222.
ABSTRACT | FULL TEXT  

Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial
Togni et al.
J Am Coll Cardiol 2007;50:1123-1131.
ABSTRACT | FULL TEXT  

Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Colombo and Chieffo
Circulation 2007;116:1424-1432.
FULL TEXT  

The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Bode and Zehender
Eur Heart J Suppl 2007;9:D10-D19.
ABSTRACT | FULL TEXT  

The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2007;50:270-285.
FULL TEXT  

Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Daemen and Serruys
Circulation 2007;116:316-328.
FULL TEXT  

Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
Jaffe and Strauss
J Am Coll Cardiol 2007;50:119-127.
ABSTRACT | FULL TEXT  

Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Moreno et al.
Eur Heart J 2007;28:1583-1591.
ABSTRACT | FULL TEXT  

Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
Cosgrave et al.
J Am Coll Cardiol 2007;49:2320-2328.
ABSTRACT | FULL TEXT  

Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent
Maeng et al.
Heart 2007;93:694-697.
ABSTRACT | FULL TEXT  

A Cause for Concern
Camenzind et al.
Circulation 2007;115:1440-1455.
FULL TEXT  

Randomized Comparison of Sirolimus and Paclitaxel Drug-Eluting Stents for Long Lesions in the Left Anterior Descending Artery: An Intravascular Ultrasound Study
Petronio et al.
J Am Coll Cardiol 2007;49:539-546.
ABSTRACT | FULL TEXT  

Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease: A Randomized Controlled Trial
Kandzari et al.
J Am Coll Cardiol 2006;48:2440-2447.
ABSTRACT | FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease
Kim et al.
Circulation 2006;114:2148-2153.
ABSTRACT | FULL TEXT  

Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry
Williams et al.
Circulation 2006;114:2154-2162.
ABSTRACT | FULL TEXT  

Assessment of coronary artery stent restenosis by 64-slice multi-detector computed tomography
Rixe et al.
Eur Heart J 2006;27:2567-2572.
ABSTRACT | FULL TEXT  

All Drug-Eluting Stents Are Equal, But Some Drug-Eluting Stents Are More Equal Than Others
Strauss
J Am Coll Cardiol 2006;48:1310-1311.
FULL TEXT  

Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice: Results From a Large Multicenter Registry
Saia et al.
J Am Coll Cardiol 2006;48:1312-1318.
ABSTRACT | FULL TEXT  

Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction
Spaulding et al.
NEJM 2006;355:1093-1104.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents in Acute Myocardial Infarction
Van de Werf
NEJM 2006;355:1169-1170.
FULL TEXT  

Common Sense, Dollars and Cents, and Drug-Eluting Stents
Vaitkus
J Am Coll Cardiol 2006;48:268-269.
FULL TEXT  

Pushing Drug-Eluting Stents Into Uncharted Territory: Simpler Than You Think--More Complex Than You Imagine
Rogers and Edelman
Circulation 2006;113:2262-2265.
FULL TEXT  

JournalScan
Malik
Heart 2006;92:719-720.
FULL TEXT  

Sirolimus vs. Paclitaxel Stents: Little Difference in REALITY
Journal Watch Cardiology 2006;2006:3-3.
FULL TEXT  

Wish List and REALITY: Choice of Stents and End Points for Treatment of De Novo Coronary Artery Lesions
Brener
JAMA 2006;295:937-938.
FULL TEXT